| Document |
Document Title |
|
WO/2017/010399A1 |
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...
|
|
WO/2017/007756A1 |
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or ...
|
|
WO/2017/004674A1 |
Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclo...
|
|
WO/2017/007755A1 |
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a sub...
|
|
WO/2017/007008A1 |
Provided are novel low-molecular-weight compounds for suppressing the inductive production of MMPs, especially MMP-9, rather than the constitutive production of MMP-2. The present invention pertains to compounds represented by formula (I...
|
|
WO/2017/001307A1 |
The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds for use in t...
|
|
WO/2017/001660A1 |
The present invention relates to the following compounds, wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2017/002120A1 |
Compounds useful for selectively eliminating senescent cells, compositions comprising same and uses thereof in treating diseases and disorders in which selective elimination of senescent cells is beneficial are provided. The compounds ar...
|
|
WO/2017/001655A1 |
Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to pr...
|
|
WO/2017/001661A1 |
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2016/208592A1 |
The present invention provides: a bicyclic heterocyclic amide derivative that is represented by formula (1), that shows excellent cancer cell sphere forming ability suppressing effect, and that is useful as an orally administrable antitu...
|
|
WO/2016/203347A1 |
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutica...
|
|
WO/2016/204261A1 |
The present invention addresses the problem of providing low-molecular compounds capable of inhibiting Src family kinases. The present invention pertains to a compound represented by general formula (I) or pharmacologically acceptable sa...
|
|
WO/2016/204270A1 |
The present invention provides a compound represented by formula (I) (in the formula, A1 and A2 each independently indicate a carbon atom or nitrogen atom; X1 indicates a substituted or unsubstituted C1-6 alkyl group or the like; n is an...
|
|
WO/2016/200690A1 |
Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising ...
|
|
WO/2016/200939A1 |
Radiofluorinated 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines targeting Fractalkine Receptor (CX3CR1) are disclosed. Methods of imaging CX3CR1-expressing tumors or cells also are disclosed.
|
|
WO/2016/199761A1 |
Provided is a plant disease control agent manifesting a high control effect against a wide range of plant pathogens. The present invention provides a compound represented by formula (I): [in the formula, each symbol is as defined in the ...
|
|
WO/2016/199789A1 |
The present invention addresses the problem of efficiently synthesizing a trifluoromethyl substituted semisquarate in a short process, in order to manufacture trifluoromethyl compounds with various functionalities. A method was developed...
|
|
WO/2016/193551A1 |
Compounds of formula I (formula I), wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2 or 3 N, O or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the tr...
|
|
WO/2016/194806A1 |
Provided are: a novel compound having antiviral action, especially HIV replication inhibitory activity; and a pharmaceutical product, especially an anti-HIV agent which contains this compound. A compound represented by formula (I). (In t...
|
|
WO/2016/197078A1 |
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided...
|
|
WO/2016/192667A1 |
Provided are a thiazolopyrimidinone compound represented by chemical formula (I), preparation method thereof, and use thereof in the preparation of drugs for treating central nervous system diseases, wherein X = O or S, Y = C or N, and w...
|
|
WO/2016/196910A1 |
The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are me...
|
|
WO/2016/183060A1 |
The present application is directed to processes and intermediates for making (S)-7-(1-((9H-purin-6-yl)amino)ethyl)-6-(3-fluorophenyl)-3-m
ethyl-5H-thiazolo[3,2-a]pyrimidin-5-one, which is an inhibitor of phosphoinositide 3-kinases (PI3K...
|
|
WO/2016/180696A1 |
The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a...
|
|
WO/2016/180743A1 |
The present invention relates to compounds of formula (I), wherein R1 to R5 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and...
|
|
WO/2016/183062A1 |
The present invention relates to salt forms of the phosphoinositide 3-kinase (PI3K) inhibitor (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-met
hyl-5H-thiazolo[3,2- a]pyrimidin-5-one, pharmaceutical compositions comprising the...
|
|
WO/2016/183063A1 |
The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-met
hyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
|
|
WO/2016/180691A1 |
The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compound...
|
|
WO/2016/182840A1 |
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of th...
|
|
WO/2016/174075A1 |
The present invention relates to herbicidal heteroaryl-alkyl-oxy-substituted heteroaryl/phenyl derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The invention further exte...
|
|
WO/2016/176118A1 |
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
|
|
WO/2016/175224A1 |
Provided is a compound represented by formula (I) that has an antiviral effect. In formula (I): A1 represents CR1AR1B, S or O; A2 represents CR2AR2B, S or O; A3 represents CR3AR3B, S or O; A4 represents CR4AR4B, S or O [wherein the ring-...
|
|
WO/2016/171142A1 |
The present invention relates to a compound potentially useful for treating or preventing SPT-related disease including congenital disease accompanied by sphingolipid accumulation, including cancer and Niemann-Pick disease.
|
|
WO/2016/168540A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):(I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A is a heterocyclic or h...
|
|
WO/2015/114666A9 |
The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens
|
|
WO/2016/161168A1 |
Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are α-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.
|
|
WO/2016/156129A1 |
The present invention relates to compounds I wherein the variables are defined as given in the description and claims. The invention further relates to uses, processes and intermediates for compounds I.
|
|
WO/2016/156597A1 |
The present invention relates to heterocyclic compounds of formula (I), their process of preparation, pharmaceutical compositions comprising these compounds and use thereof, optionally in combination with other antibacterial agents and/o...
|
|
WO/2016/161382A1 |
Compounds for use in the treatment of human immunodeficiency (HIV) infection are disclosed. The compounds have the following Formula (la): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A, A', R1 and R2 ar...
|
|
WO/2016/154547A1 |
The present invention provides methods using a compound capable of chelating a metal (e.g., iron) for treating and/or preventing infectious diseases. In particular, the metal chelators are desferrithiocin analogs, desazadesfemthiocin ana...
|
|
WO/2016/144351A1 |
Disclosed are compounds of Formula (I), including all geometric and stereoisomers, N-oxides, and salts thereof, Formula (I) wherein Q is Formula (I) and A, R1, m, X1, X2, X3, X4, Y1, Y2 and Y3 are as defined in the disclosure. Also discl...
|
|
WO/2016/144814A1 |
Analogs of largazole are described herein. Methods of treating cancer, blood disorders, autoimmune disease, and Alzheimer's Disease using largazole analogs and pharmaceutical compositions comprising the same are additionally described he...
|
|
WO/2016/144665A1 |
Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing ...
|
|
WO/2016/138199A1 |
The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X1, X2, X3, X4, X5, Y, WR2,R3, R4, R5, R6, R7 and AA and other moieties are as defined herein, or a stereoisome...
|
|
WO/2016/138335A1 |
The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorde...
|
|
WO/2016/137788A1 |
The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
|
|
WO/2016/134450A1 |
The present invention provides imidazopyridazine compounds or imidazothiadiazole compounds of Formula I having the structure: (I) wherein X1, X2, X3, X4, X5, Y, W, R1, R2, R3, R4, R5 and (II) are as defined herein, or a stereoisomer, tau...
|
|
WO/2016/127916A1 |
This application relates to a substituted amino six-membered saturated heterocyclic fat, used as a long-acting DPP-IV inhibitor, as represented by the general formula I, a method for preparing same, a pharmaceutical combination thereof, ...
|
|
WO/2016/126935A1 |
The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and dis...
|
